

Une tri-thérapie contre le paludisme

(artémether-luméfantrine+atovaquone-proguanil)

Quelques résultats & retour d'expérience du projet ASAAP financé par EDCTP




Oumou Maïga-Ascofaré, Jérôme Clain, et le consortium du projet ASAAP

Kumasi Centre for Collaborative Research (KCCR)
KNUST, Ghana

UMR MERIT - UPCité, IRD, Inserm
Paris, France

Timeline of the use of curative antimalarials




Rationale for antimalarial bitherapies (ACT) & tritherapies (T-ACT)

- T-ACT** {
- Artemisinin derivative ($t_{1/2}$ 2 hr)
 - TWO** partner drugs ($t_{1/2} \geq \sim 3$ days)
- ↳ Lumefantrine + amodiaquine
 - ↳ Lumefantrine + **atovaquone-proguanil (AL+AP)**

Oxford University (enregistrement en cours)


Projet ASAAP



Rationale for artemether-lumefantrine+atovaquone-proguanil (AL+AP)

Atovaquone-Proguanil:


- Off patent/under-used
- PK: similar $t_{1/2}$ with lumefantrine
--> protection partner drug
- Targets the mitochondrion
--> Protection from ART-R
- Multi-stage activities:
Blood + Liver + Vector
Curative + prophylactic + transmission-blocking



Rationale for artemether-lumefantrine+atovaquone-proguanil (AL+AP)

Atovaquone-Proguanil:

- Off patent/under-used
- PK: similar $t_{1/2}$ with lumefantrine --> protection partner drug
- Targets the mitochondrion --> Protection from ART-R
- Multi-stage activities:
Blood + Liver + Vector
Curative + prophylactic + transmission-blocking



Objectives of the ASAAP project

Compare AL + AP (atovaquone-proguanil) and AL + placebo

- **per-protocol (PP) efficacy at day-28**
- other efficacy outcomes (day-42 & mITT)
- safety
- pharmacokinetics (pop. PK & day-7)
- duration post-treatment protection
- transmission-blocking
- selection of drug resistance markers


- phase 3: non inferiority trial (.... 2017, Afrique)
- 1 664 patients, 4 countries
- 0.5 to 10 years old
- Weight-based treatment algorithm
- 1:1 ratio of control and experimental treatments
- randomised, blinded, placebo-controlled



Coordination

- Dr. Oumou Maïga-Ascofaré
- **KCCR - KNUST**
- Ghana / Germany

Germany (**BNITM**), France (**IRD** Paris/Montpellier)



Objectives of the ASAAP project

Compare AL + AP (atovaquone-proguanil) and AL +placebo

- **per-protocol (PP) efficacy at day-28**
- other efficacy outcomes (day-42 & mITT)
- safety
- pharmacokinetics (pop. PK & day-7)
- duration post-treatment protection
- transmission-blocking
- selection of drug resistance markers

- phase 3: non inferiority trial (.... 2017, Afrique)
- 1 664 patients, 4 countries
- 0.5 to 10 years old
- Weight-based treatment algorithm
- 1:1 ratio of control and experimental treatments
- randomised, blinded, placebo-controlled



Coordination

- Dr. Oumou Maïga
- KCCR - KNUST
- Ghana / Germany

Mali – Prof
Abdoulaye Djimde

MRTC



Ghana – Prof John
Amuasi

KCCR



Gabon - Prof Ghyslain
Mombo Ngoma

CERMEL




Benin - Prof Achille
Massougbojji

IRCB




Attrition

Recruitment: January 2022 to March 2024



Country	Participants (N / %)
Benin	306 / 18.4
Gabon	356 / 21.4
Ghana	452 / 27.2
Mali	550 / 33
Total	1 664 / 100



Retour d'expérience

- Consortium +++++ :
 - Équilibrer les responsabilités
 - critères EDTCP3 +++++
 - responsabilités Nord / Sud ; diversité « langues » ; parité
- Capacity building, stakeholder engagement
- Social sciences, cost-effectiveness, adherence to the intervention/product
- Partenaire industriel (EDTCP3) → produit commercialisable en fin de projet
- Limiter le nombre des livrables
- A l'écriture du projet **TOUS** les critères comptent (pas de redondance entre catégories) !!
- Après : bonne communication « ouverte » avec EDTCP

Thank you

